PSTV 8-K — Smart Summary

78% reduction

Plus Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on August 7, 2025, at which holders of 29,973,272 of 60,490,101 outstanding shares were represented, constituting a quorum. Stockholders voted on five proposals covering director elections, a stock issuance, a reverse stock split authorization, executive compensation, and a stock incentive plan amendment.

Item 5.07 — Submission of Matters to a Vote of Security Holders

Director Elections

Howard Clowes — 18,904,550 for / 774,122 against (96.05% approval)
An van Es-Johansson, M.D. — 18,743,348 for / 935,324 against (95.24% approval)
Richard J. Hawkins — 18,920,875 for / 757,797 against (96.14% approval)
Marc H. Hedrick, M.D. — 18,764,355 for / 914,317 against (95.35% approval)
Robert Lenk, Ph.D. — 18,934,411 for / 774,261 against (96.06% approval)
Kyle Guse, Esq., MBA, CPA — 18,698,728 for / 979,944 against (95.02% approval)

Management Proposals

Issuance of Common Stock to Lincoln Park Capital Fund (Nasdaq Rule 5635(d)) — 18,469,325 for / 1,114,462 against / 94,885 abstain (94.23% approval) — passed
Reverse Stock Split Authorization (1-for-2 to 1-for-250) — 25,678,339 for / 4,151,673 against / 143,260 abstain (86.07% approval) — passed
Advisory Vote on Named Executive Officer Compensation — 16,714,842 for / 858,028 against / 2,105,802 abstain (95.11% approval) — passed
Fifth Amendment and Restatement of the 2020 Stock Incentive Plan — 16,886,510 for / 761,060 against / 2,031,102 abstain (95.69% approval) — passed

§ MORE SUMMARIES